BioCentury
ARTICLE | Company News

EpiVax, Novozymes deal

February 18, 2013 8:00 AM UTC

The companies will combine EpiVax's Tregitope technology with Novozymes' Albufuse albumin-based half-life extension technology to develop therapies for Type I diabetes with enhanced pharmacokinetic an...